SCHEMBL5774909

SCHEMBL5774909

CC(C)(C)OC(=O)c1cnc(-c2ccc(Cl)cc2)c(-c2ccc(Cl)cc2)n1

nearest known ligand 0.53

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 16/20 0.53
CKS1B P61024 2/20 0.41
SKP1 P63208 2/20 0.41
SKP2 Q13309 2/20 0.41
HPGDS O60760 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2704945 0.77 CNR1 (0.67) CNR1
SCHEMBL5773432 0.77 CNR1 (0.62) CNR1
SCHEMBL4252468 0.76 CNR1 (0.61) CNR1
SCHEMBL4677223 0.76 CNR1 (0.44) CNR1
SCHEMBL5452416 0.74 CNR1 (0.61) CNR1
SCHEMBL12474883 0.74 TRPA1 (0.57)
SCHEMBL5771581 0.74 CNR1 (0.63) CNR1
SCHEMBL2702037 0.72 KDM4E (0.48) CNR1
SCHEMBL441931 0.72 CNR1 (0.47) CNR1
SCHEMBL4676483 0.72 CNR1 (0.46) CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060135523-A1 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator ASTRAZENECA AB (SE) 2006-06-22 US claimed
EP-1641779-A1 2-SUBSTITUED 5, 6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATOR. AstraZeneca AB (SE) 2006-04-05 EP claimed
WO-2004111033-A1 2-SUBSTITUED 5, 6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATOR. ASTRAZENECA AB (SE) 2004-12-23 WO claimed
EP-4307380-A1 DISPLAY PANEL AND DISPLAY DEVICE Huawei Technologies Co., Ltd. (CN) 2024-01-17 EP disclosed
CN-107400394-B A kind of pearlescent pigment and preparation method thereof being directly used in electrostatic powder coating 福建坤彩材料科技股份有限公司 2019-10-15 CN disclosed
CN-107293593-B Display panel and display device 上海天马微电子有限公司 2019-09-24 CN disclosed
CN-110119217-A The touch screen and terminal device of tin indium oxide film layer structure 深圳莱宝高科技股份有限公司 2019-08-13 CN disclosed
CN-208954995-U A kind of thin-film solar cells 北京铂阳顶荣光伏科技有限公司 2019-06-07 CN disclosed
CN-109827918-A The measuring method of silicone content in tin-doped indium oxide powder 广西壮族自治区冶金产品质量检验站 2019-05-31 CN disclosed
CN-109827953-A The measuring method of iron, aluminium, lead, nickel, copper, cadmium, chromium and thallium content in tin-doped indium oxide powder 广西壮族自治区分析测试研究中心 2019-05-31 CN disclosed
CN-109813741-A The method that material phase analysis is carried out to tin-doped indium oxide powder using X-ray diffraction method 广西壮族自治区冶金产品质量检验站 2019-05-28 CN disclosed
CN-202601714-U Combined electrode suitable for high-power GaN-based LED chip SHIKETE PHOTOELECTRIC MATERIAL KUNSHAN CO LTD 2012-12-12 CN disclosed
CN-102709431-A Composition electrode applicable to large-power gallium nitride (GaN) based light-emitting diode (LED) chip SHIKETE PHOTOELECTRIC MATERIAL KUNSHAN CO LTD 2012-10-03 CN disclosed
CN-102480006-A Transparent metamaterial SHENZHEN KUANG CHI INST 2012-05-30 CN disclosed
CN-102265411-A Light receiving element, light receiving element array, method for manufacturing light receiving element, and method for manufacturing light receiving element array 2011-11-30 CN disclosed
WO-2006071586-A1 BORON COMPOUNDS AS STABILIZERS IN PHOTOTHERMOGRAPHIC MATERIALS CARESTREAM HEALTH, INC. (US) 2006-07-06 WO disclosed
US-20060135523-A1 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator ASTRAZENECA AB (SE) 2006-06-22 US disclosed
EP-1641779-A1 2-SUBSTITUED 5, 6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATOR. AstraZeneca AB (SE) 2006-04-05 EP disclosed
WO-2006028849-A1 DEVELOPER DISPERSIONS FOR THERMALLY DEVELOPABLE MATERIALS EASTMAN KODAK COMPANY (US) 2006-03-16 WO disclosed
WO-2004111033-A1 2-SUBSTITUED 5, 6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATOR. ASTRAZENECA AB (SE) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135523-A1 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator CNR2, CNR1, GPR55 CNR1 2/4885CKS1B 1482/4885SKP1 2266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.